Biogen (NASDAQ:BIIB) Issues FY 2025 Earnings Guidance

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Biogen (NASDAQ:BIIB - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 15.500-16.000 for the period, compared to the consensus estimate of 14.980. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BIIB shares. Mizuho lowered their target price on shares of Biogen from $207.00 to $169.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Piper Sandler reiterated a "neutral" rating and issued a $115.00 price objective on shares of Biogen in a report on Thursday, June 12th. The Goldman Sachs Group lowered their price target on Biogen from $219.00 to $197.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Oppenheimer set a $205.00 price objective on Biogen in a research report on Friday, May 2nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Biogen in a research note on Thursday, June 12th. Twenty-one analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat, Biogen has a consensus rating of "Hold" and a consensus price target of $186.37.

Biogen Stock Up 1.5%

BIIB stock traded up $1.92 during trading on Thursday, reaching $128.56. The stock had a trading volume of 1,447,941 shares, compared to its average volume of 1,550,927. The company has a market capitalization of $18.84 billion, a price-to-earnings ratio of 12.69, a P/E/G ratio of 1.85 and a beta of 0.14. The company has a quick ratio of 1.01, a current ratio of 1.44 and a debt-to-equity ratio of 0.27. The company's 50 day moving average is $129.68 and its two-hundred day moving average is $132.05. Biogen has a one year low of $110.04 and a one year high of $219.44.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, topping analysts' consensus estimates of $4.11 by $1.36. Biogen had a return on equity of 14.03% and a net margin of 15.07%. During the same period last year, the company earned $5.28 earnings per share. The firm's quarterly revenue was up 7.3% compared to the same quarter last year. Equities research analysts forecast that Biogen will post 15.83 EPS for the current year.

Insider Buying and Selling

In other Biogen news, insider Rachid Izzar sold 2,223 shares of the company's stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the transaction, the insider directly owned 6,330 shares in the company, valued at approximately $854,550. This represents a 25.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.18% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biogen

An institutional investor recently raised its position in Biogen stock. Empowered Funds LLC increased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 64.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,054 shares of the biotechnology company's stock after purchasing an additional 2,777 shares during the period. Empowered Funds LLC's holdings in Biogen were worth $965,000 as of its most recent SEC filing. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.